吡咯替尼联合卡培他滨在老年HER-2阳性晚期乳腺癌患者中的应用效果  

Effect of pyrotinib combined with capecitabine in elderly patients with HER-2-positive advanced breast cancer

作　　者：莫淑芬 钟海鸣[1] 许靖靖 郁德杰 MO Shufen;ZHONG Haiming;XU Jingjing;YU Dejie(Department of Medical Oncology,Guangdong Agricultural Reclamation Central Hospital,Guangdong,Zhanjiang 524000,China)

机构地区：[1]广东省农垦中心医院肿瘤内科,广东湛江524000

出　　处：《中国医药科学》2023年第4期83-86,共4页China Medicine And Pharmacy

基　　金：广东省湛江市科技计划项目(2020B01201)。

摘　　要：目的观察吡咯替尼联合卡培他滨(Cap)在老年人类表皮生长因子受体-2(HER-2)阳性晚期乳腺癌患者中的应用效果。方法选取2019年6月至2021年6月广东省农垦中心医院收治的40例老年HER-2阳性晚期乳腺癌患者,通过随机数表法分为两组,每组各20例,对照组接受Cap治疗,观察组接受Cap联合吡咯替尼治疗,治疗2周期时,评估两组临床疗效;于治疗前后比较两组血清肿瘤标志物[癌胚抗原(CEA)、糖类抗原125(CA125)];比较两组毒副反应发生情况;随访至2022年6月,比较两组无进展生存期(PFS)。结果观察组临床控制率(DCR)为95.00%,高于对照组的65.00%,差异有统计学意义(P<0.05);治疗后,两组血清CEA、CA199水平显著下降,且观察组低于对照组(P<0.05)。随访时间截至2022年6月,对照组PFS平均为9.286(95%CI:8.213~10.359);观察组PFS平均为11.314(95%CI:10.889~11.739),观察组PFS长于对照组,差异有统计学意义(P<0.05);两组毒副反应发生率比较,差异无统计学意义(P>0.05)。结论吡咯替尼联合Cap治疗老年HER-2阳性晚期乳腺癌患者,可提高DCR,降低肿瘤标志物水平,延长PFS。Objective To observe the effect of pyrotinib combined with capecitabine(Cap)in elderly patients with human epidermal growth factor receptor-2(HER-2)-positive advanced breast cancer.Methods A total of 40 elderly patients with HER-2-positive advanced breast cancer who were adm itted to Guangdong Agricultural Reclamation Central Hospital from June 2019 to June 2021 were selected and divided into two groups by the random number table method,with 20 cases in each group.The control group was treated with Cap,while the observation group was treated with Cap combined with pyrotinib.At the time of 2 cycles of treatment,the clinical efficacy in the two groups was evaluated.Serum tumor markers including carcinoembryonic antigen(CEA)and carbohydrate antigen 125(CA125)were compared between the two groups before and after treatment.The occurrence of toxic and side effects was compared between the two groups.The two groups were followed up until June 2022 to compare the progression-free survival(PFS).Results The clinical disease control rate(DCR)of the observation group(95.00%)was higher than that of the control group(65.00%),with statistically significant difference(P<0.05).After treatment,the serum CEA and CA199 levels in the two groups decreased significantly,and the levels in the observation group were lower than those in the control group(P<0.05).By the follow-up cutoff of J une 2022,the average P FS of the control group was 9.286(95%CI:8.213-10.359);the average PFS of the observation group was 11.314(95%CI:10.889-11.739).The PFS of the observation group was longer than that of the control group,with statistically significant difference(P<0.05).There was no statistically significant difference in the incidence of toxic and side effects between the two groups(P>0.05).Conclusion The combination of pyrotinib and Cap in the treatment of elderly patients with HER-2-positive advanced breast cancer can increase DCR,reduce the levels of tumor markers and prolong P FS.

关 键 词：晚期乳腺癌 人类表皮生长因子受体-2 卡培他滨 吡咯替尼 

分 类 号：R737.9[医药卫生—肿瘤]